Nevertheless, whether using functional genomics or metabolomics methods via Possemato et al. [21]'s loss-of-function RNA-interference screen or Locasale et al. [8]'s glucose-derived carbon flux, both groups identified purported targets of interest and mined known databases of cancer copy number alterations to determine that PHGDH on chromosome 1p12 is amplified in some 6% of breast cancers and 40% of melanomas. This evidence concerns the gene PHGDH and breast carcinoma.